Patents by Inventor Stephen D. Hess

Stephen D. Hess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of modulating processes mediated by excitatory amino acid receptors
    Patent number: 6956049
    Abstract: In accordance with the present invention, there are provided methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: October 18, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Nicholas D. P. Cosford, Ian A. McDonald, Stephen D. Hess, Mark A. Varney
  • Human metabotropic glutamate receptors, nucleic acids encoding same and uses thereof
    Patent number: 6485919
    Abstract: In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtypes and the proteins encoded thereby. In a particular embodiment, the invention nucleic acids encode mGluR1, mGluR2, mGluR3 and mGluR5 subtypes of human metabotropic glutamate receptors. In addition to being useful for the production of metabotropic glutamate receptor subtypes, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing novel metabotropic glutamate receptor subtypes, the present invention also comprises methods for using such receptor subtypes to identify and characterize compounds which affect the function of such receptors, e.g., agonists, antagonists, and modulators of glutamate receptor function.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: November 26, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Lorrie Daggett, Steven B. Ellis, Chen Liaw, Aaron Pontsler, Edwin C. Johnson, Stephen D. Hess
  • Human metabotropic glutamate receptors, nucleic acids encoding same and uses thereof
    Patent number: 6413764
    Abstract: In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtypes and the proteins encoded thereby. In a particular embodiment, the invention nucleic acids encode mGluR1, mGluR2, mGluR3 and mGluR5 subtypes of human metabotropic glutamate receptors. In addition to being useful for the production of metabotropic glutamate receptor subtypes, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing novel metabotropic glutamate receptor subtypes, the present invention also comprises methods for using such receptor subtypes to identify and characterize compounds which affect the function of such receptors, e.g., agonists, antagonists, and modulators of glutamate receptor function.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: July 2, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Lorrie Daggett, Steven B. Ellis, Chen Liaw, Aaron Pontsler, Edwin C. Johnson, Stephen D. Hess
  • MGluR5 antagonists for the treatment of pain and anxiety
    Publication number: 20010056084
    Abstract: The invention provides the use of selective mGluR5 antagonists for the treatment of pain and anxiety, and the use of mGluR antagonists for the treatment of pain, whereby analgesic effect is achieved by interaction of said antagonists primarily or predominantly at peripheral mGluR receptors.
    Type: Application
    Filed: March 29, 2001
    Publication date: December 27, 2001
    Inventors: Hans Allgeier, Nicholas David Cosford, Peter Josef Flor, Fabrizio Gasparini, Conrad Gentsch, Stephen D. Hess, Edwin Carl Johnson, Rainer Kuhn, Mark Tricklebank, Laszlo Urban, Mark Andrew Varney, Gonul Velicelebi, Katharine Walker
  • Cation-based bioassay using human metabotropic glutamate receptors
    Patent number: 6001581
    Abstract: In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtypes and the proteins encoded thereby. In a particular embodiment, the invention nucleic acids encode mGluR1, mGluR2, mGluR3 and mGluR5 subtypes of human metabotropic glutamate receptors. In addition to being useful for the production of metabotropic glutamate receptor subtypes, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing novel metabotropic glutamate receptor subtypes, the present invention also comprises methods for using such receptor subtypes to identify and characterize compounds which affect the function of such receptors, e.g., agonists, antagonists, and modulators of glutamate receptor function.
    Type: Grant
    Filed: January 9, 1995
    Date of Patent: December 14, 1999
    Assignee: Sibia Neurosciences, Inc.
    Inventors: Edwin C. Johnson, Stephen D. Hess
  • Methods for identifying compounds that modulate metabotropic glutamate receptor activity
    Patent number: 5807689
    Abstract: In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtypes and the proteins encoded thereby. In a particular embodiment, the invention nucleic acids encode mGluR1, mGluR2, mGluR3 and mGluR5 subtypes of human metabotropic glutamate receptors. In addition to being useful for the production of metabotropic glutamate receptor subtypes, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing novel metabotropic glutamate receptor subtypes, the present invention also comprises methods for using such receptor subtypes to identify and characterize compounds which affect the function of such receptors, e.g., agonists, antagonists, and modulators of glutamate receptor function.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 15, 1998
    Assignee: Sibia Neurosciences, Inc.
    Inventors: Lorrie Daggett, Steven B. Ellis, Chen Liaw, Aaron Pontsler, Edwin C. Johnson, Stephen D. Hess